Rob Sahr develops strategies for life science companies to maximize exclusivity for therapeutic and diagnostic products. Rob assists clients with building global patent portfolios aligned with product life cycle, and advises clients on regulatory exclusivities, patent term extensions, Orange Book listings and biosimilars.
In addition to pharma and biotech companies, Rob works with universities, research institutions and venture capital investors, providing patentability and freedom to operate assessments, non-infringement and invalidity opinions, performing IP diligence, and preparing agreements.
Rob has also assisted federal grant recipients and contractors with Bayh-Dole compliance, including use of iEdison.
Rob has worked extensively in technologies including antibodies, vaccines, chimeric antigen receptors, cell therapies, synthetic biology, medical devices, imaging agents, biologics and small molecules for new disease indications.
Before beginning his career in the law, Rob was a neuroscientist engaged in drug discovery at Eli Lilly and Company.
Rob is recognized in the IAM Patent 1000: The World’s Leading Patent Professionals.